Why Doximity Stock Plunged Today

Doximity reported mixed Q4 results: sales rose 5% and free cash flow increased 11%, but earnings missed expectations and the stock fell 24%. Management guided 2027 revenue growth to just 3% to 5% and signaled declining adjusted EBITDA margins as AI spending rises. Offset by some AI traction, nearly half of prescribers used AI tools and AI search/transcribe users tripled in nine months, but the outlook remains cautious.

Analysis

The market is reacting less to the quarter itself than to the signal that DOCS is entering a classic “invest first, monetize later” phase just as its core demand environment softens. That is a dangerous mix for a high-multiple platform: when growth decelerates and margins compress simultaneously, the equity stops being valued on product optionality and starts trading on execution credibility. The immediate winner from this reset is not another healthcare ad platform, but any larger digital health or workflow vendor with an adjacent AI roadmap and better balance-sheet patience; customers are likely to benchmark DOCS pricing against broader software alternatives if AI features remain bundled rather than monetized.

The second-order issue is that AI adoption metrics can be misleading near-term. High usage does not automatically translate into near-term revenue if the product is still acting as a retention tool or workflow enhancer rather than a priced module; in that case, AI becomes a cost center before it becomes an ARR engine. That creates a months-long overhang where every incremental AI rollout can depress margins before the market is willing to assign credit for future monetization.

The setup also argues for a “show-me” regime over the next 1-2 quarters. If macro stabilizes, the stock can rebound quickly because expectations are now low and the valuation has room to re-rate, but absent evidence of AI attach-rate converting into paid seats, any bounce is likely to be sold. The key risk to the bear case is that management finds a way to repackage AI into higher-priced clinical workflows faster than expected, which would make the current de-rating look excessive within 2-3 reporting periods.

Contrarianly, the move may be partially overdone if investors are conflating softer ad demand with structural competitive loss. The network remains strategically hard to displace, and in healthcare, distribution often matters more than feature sophistication; if DOCS keeps physicians engaged, it can outlast a cyclical budget pause. Still, in the near term the burden of proof has shifted squarely to monetization, not adoption.

Key Decisions for Investors

• Short DOCS on strength for a 1-3 month horizon; the setup favors continued multiple compression until management proves AI can lift revenue per user rather than just engagement.
• If looking for a cleaner relative-value expression, pair long a profitable healthcare workflow/software name with short DOCS over the next 1-2 quarters; the trade benefits if the market continues to reward monetization certainty over product novelty.
• Sell out-of-the-money DOCS calls into post-earnings volatility over the next 30-60 days; implied expectations should stay elevated while fundamentals remain in a prove-it phase.
• For longer-term investors, wait for one clean quarter of re-acceleration in revenue and stabilization in adjusted EBITDA margin before initiating longs; current risk/reward is poor because downside remains tied to both growth and margin disappointment.
• Use a tighter stop on any contrarian long only if management shows AI is converting into paid clinical suite expansion within the next 2 quarters; otherwise the thesis is still too narrative-heavy.